14/06/2013
L
By: Presswatch
Glaxo Investigates Allegations of Bribery in China
Pharma giant GlaxoSmithKline is investigating allegations from an anonymous tipster that its sales staff in China was involved in widespread bribery of doctors to prescribe drugs, in some cases for unauthorized uses, between 2004 and 2010. The company, alongside other pharmaceutical makers, is also being investigated by US authorities over whether it paid bribes to foreign government officials. Chief Executive Andrew Witty, who took the helm in 2008, has said making the company more transparent is a priority.
Glaxo under investigation over allegations of corruption in China
Pharma giant GlaxoSmithKline is being investigated over allegations by an anonymous whistleblower that its sales staff in China were involved in the widespread bribing of doctors to prescribe drugs, in some cases for unauthorized use, between 2004 and 2010. The company, along with other drugmakers, is also being investigated by US authorities over whether it has paid bribes to foreign public officials. Administrator Andrew Witty, who took the helm in 2008, said making the company more transparent was a priority.
Ed.: according to the available data (Cegedim Strategic Data), as of 2011 in China there are 65,827 Scientific Representatives with a growing trend (see
